Deep knowledge on 
 small-molecule drugs and 
 the 100,000 global patents 
 covering them 

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: FROVA

« Back to Dashboard
Frova is a drug marketed by Endo Pharms and Mylan Pharms Inc and is included in two NDAs. It is available from four suppliers. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-four patent family members in thirty-three countries.

The generic ingredient in FROVA is frovatriptan succinate. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the frovatriptan succinate profile page.

Summary for Tradename: FROVA

Patents:2
Applicants:2
NDAs:2
Suppliers / Packagers: see list5

Clinical Trials for: FROVA

Frovatriptan and Menstrual Migraine
Status: Terminated Condition: Frovatriptan; Menstrual Migraine

Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine
Status: Completed Condition: Migraine

Prevention of Menstrual Migraines: Using Frovatriptan or Placebo During Hormone Free Intervals
Status: Completed Condition: Migraines; Bleeding; Spotting

A Research Study To Evaluate If Frovatriptan Is Safe And Effective In Preventing Migraine Headache After Fasting
Status: Completed Condition: Migraine

Frovatriptan as a Transitional Therapy in Medication Overuse Headache
Status: Recruiting Condition: Medication Overuse Headache; Analgesic Overuse Headache

Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment) Of Menstrual Migraine
Status: Completed Condition: Menstrual Migraine (MM) Headaches

Safety and Tolerability of Frovatriptan to Prevention of Menstrually Associated Migraine (MAM) Headaches
Status: Completed Condition: Migraine

A Double Blind Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine
Status: Completed Condition: Migraine

A Controlled Trial to Investigate the Efficacy and Safety of Frovatriptan to Prevent Menstrual Migraine
Status: Completed Condition: Migraine

Renal Denervation by Allegro System in Patients With Resistant Hypertension
Status: Recruiting Condition: Renal Denervation; Resistant Hypertension; Standard Medication

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Pharms
FROVA
frovatriptan succinate
TABLET;ORAL021006-001Nov 8, 2001RXYes5,464,864<disabled> <disabled>
Endo Pharms
FROVA
frovatriptan succinate
TABLET;ORAL021006-001Nov 8, 2001RXYes5,827,871<disabled> <disabled>
Mylan Pharms Inc
FROVATRIPTAN SUCCINATE
frovatriptan succinate
TABLET;ORAL202931-001Aug 28, 2014RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: FROVA

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Endo Pharms
FROVA
frovatriptan succinate
TABLET;ORAL021006-001Nov 8, 20015,464,864<disabled>
Endo Pharms
FROVA
frovatriptan succinate
TABLET;ORAL021006-001Nov 8, 20015,962,501<disabled>
Endo Pharms
FROVA
frovatriptan succinate
TABLET;ORAL021006-001Nov 8, 20015,917,054<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: FROVA

Drugname Dosage Strength RLD Submissiondate
frovatriptan succinateTablets2.5 mgFrova3/9/2011

Non-Orange Book Patents for Tradename: FROVA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,637,611 Medicaments<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: FROVA

Country Document Number Publication Date
Netherlands300103Feb 03, 2003
Singapore47877Apr 17, 1998
Slovenia9200125Dec 31, 1992
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc